- Tempus buys out cancer genomics partner Personalis in $1.5 billion dealTempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.Fierce Biotech · 4d ago↗ source
- Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic medsScribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.Fierce Biotech · 5d ago↗ source
- BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’Bristol Myers Squibb has entered into an expanded collaboration with Nvidia to create the biggest supercomputer for drug R&D, according to the announcement.